All In Biotech

Drug Trial Radar · NCT05090280

Pharmacokinetics of Oxycodone and PF614 Co-Administered with Nafamostat (PF614-MPAR-101)

A Single Dose Study to Evaluate the Pharmacokinetics of Oxycodone and PF614 When PF614 Solution is Co-Administered with Nafamostat, As an Immediate Release Solution And/or Extended Release (ER) Capsule Formulations in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 111 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

111

Actual

Start

Dec 1, 2021

Primary completion

Apr 26, 2023

Study completion Apr 26, 2023

Sponsor

Lead sponsor
Ensysce BiosciencesIndustry
Sponsor type
Industry
Collaborators
Quotient Sciences; National Institute on Drug Abuse (NIDA)
First posted
Oct 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A single dose study to assess the pharmacokinetics (PK) of oxycodone, when PF614 is solution is administered alone and with nafamostat as an immediate-release (IR) solution and/or extended-release (ER) capsule prototypes.

Conditions

  • Pharmacokinetics

Interventions

  • PF614 solutionDrug

    PF614 solution is an oxycodone prodrug

  • Naltrexone HydrochlorideDrug

    Naltrexone 50 mg has been selected to be administered on Day -1 (single dose), Day 1 (BID), and Day 2 (single-dose) to reduce opioid-related adverse effects.

  • Nafamostat MesylateDrug

    Maximum dose of 10 mg nafamostat co-administered with PF614 solution. Nafamostat will be dosed as an immediate-release (IR) solution or as prototype extended-release (ER) capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetic Tmax [Time to Maximum Plasma Concentration]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
  2. Pharmacokinetic Cmax [Maximum Plasma Concentration]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
  3. Pharmacokinetic C24 [Plasma concentration at 24 hours]Time frame: 24 hours
  4. Pharmacokinetic AUC [Area Under the Curve]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
  5. Pharmacokinetic AUC(0-last)Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours
  6. Pharmacokinetic T1/2 [Half-life]Time frame: pre-dose, 0.5,1,1.5,2,3,4,6,8,12,16,24,36,48 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quotient Sciences

    Miami, Florida

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.